Anthos Therapeutics, Inc.

ACTIVE

55 Cambridge Pkwy, 马萨诸塞州米德尔塞克斯县, Massachusetts, United Stateswww.anthostherapeutics.comHolding11–50 employeesEstablished: 2018-01-01

Clinical Trials

6 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

2018

Overview

Trial Phase Distribution

Phase

Trials

Phase 3

39.1%

Phase 1

34.8%

Phase 2

13.0%

Trial Status Distribution

Active, not recruiting

26.1%

Completed

4.3%

Recruiting

56.5%

Terminated

13.0%

Clinical Trials

Trials sponsored by this organization (23)

A multicenter, randomized, open-label, blinded endpoint evaluation, phase 3 study comparing the effect of abelacimab relative to apixaban on venous thromboembolism (VTE) recurrence and bleeding in patients with cancer associated VTE (ASTER)

Phase 1

Recruiting

interventional

Jun 20241,297 participants

A multicenter, randomized, open-label, blinded endpoint evaluation, phase 3 study comparing the effect of abelacimab relative to dalteparin on venous thromboembolism (VTE) recurrence and bleeding in patients with gastrointestinal (GI)/genitourinary (GU) cancer associated VTE (Magnolia)

Phase 1

Recruiting

interventional

Jun 20241,008 participants

Study to evaluate whether or not abelacimab is safe and effective in preventing stroke in patients with atrial fibrillation who are considered as high risk of stroke, but who have been deemed to be unsuitable candidates for currently available oral anticoagulants.

Phase 3

Recruiting

interventional

Mar 20241,900 participants

Abelacimab versus apixaban in the treatment of cancer associated VTE (ASTER)

Recruiting

interventional

Jan 202466 participants

A study to compare how safe and well tolerated study drug Abelacimab (MAA868) is compared to another drug called Rivaroxaban in patients with heart condition that causes an irregular and abnormally fast heart rate

Phase 1

Active, not recruiting

interventional

Dec 20231,200 participants

A study of abelacimab in patients with atrial fibrillation deemed unsuitable for oral anticoagulation (LILAC)

Recruiting

interventional

Sep 2023125 participants

A Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaLuate the effIcacy and safety of abeLacimab in high-risk patients with Atrial fibrillation who have been deemed unsuitable for oral antiCoagulation (LILAC)

Phase 1

Recruiting

interventional

Feb 20231,963 participants

Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)

Phase 3

Recruiting

interventional

Dec 20222,500 participants

Page 1 of 3

Approvals

No approval data available

News

No news articles found

Back to Organizations